Search Thermo Fisher Scientific
Disclaimer
Clicking the images or links will redirect you to a website hosted by BenchSci that provides third-party scientific content. Neither the content nor the BenchSci technology and processes for selection have been evaluated by us; we are providing them as-is and without warranty of any kind, including for use or application of the Thermo Fisher Scientific products presented.
FIGURE: 1 / 1
Ipilimumab Antibody (A01858-40) in ELISA
Anti-Ipilimumab Antibody (4H6) [biotin], mAb, Mouse (GenScript, A01858-40) binds with Ipilimumab, while the antibody does not recognize human IgG Fc fragment (data not shown). Coating antigen: Ipilimumab, 1 µg/mL. Anti-Ipilimumab antibody (GenScript, A01858-40) dilution start from 1,000 ng/mL. EC50=3.85 ng/mL.
Product Details
A01858-40
Product Specifications
Species Reactivity
Chemical
Host/Isotype
Mouse
/ IgG1
Class
Monoclonal
Type
Antibody
Clone
4H6
Immunogen
Ipilimumab
Conjugate
Form
Lyophilized
Purification
Protein A
Storage buffer
PBS, pH 7.4, with 1% BSA
Contains
0.02% sodium azide
Storage conditions
-20°C or -80°C if preferred
Shipping conditions
Ambient (domestic); Wet ice (international)
Product Specific Information
Reconstitute the lyophilized antibody with deionized water (or equivalent) to a final concentration of 0.5 mg/ml.
Ipilimumab (Yervoy) is a humanized monoclonal antibody that is approved by the U.S. Food and Drug Administration for the treatment of patients with unresectable or metastatic melanoma. Ipilimumab works to activate the immune system by targeting CTLA-4 (Cytotoxic T-lymphocyte protein 4), a negative regulator of cytotoxic T-lymphocyte activity. Ipilimumab binds to CTLA-4, blocking the inhibitory signal, which allows the cytotoxic T-lymphocytes to destroy the cancer cells Anti-Ipilimumab Antibody (4H6) [biotin], mAb, Mouse is produced from a hybridoma resulting from the fusion of partner and B-lymphocytes obtained from a mouse immunized with Ipilimumab.
Target Information
Ipilimumab (Yervoy) is a humanized monoclonal antibody that is approved by the U.S. Food and Drug Administration for the treatment of patients with unresectable or metastatic melanoma. Ipilimumab works to activate the immune system by targeting CTLA-4 (Cytotoxic T-lymphocyte protein 4), a negative regulator of cytotoxic T-lymphocyte activity. Ipilimumab binds to CTLA-4, blocking the inhibitory signal, which allows the cytotoxic T-lymphocytes to destroy the cancer cells.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
References (0)
Have you cited this product in a publication?
Let us know so we can reference it here.
Bioinformatics
Protein Aliases: BMS-734016; MDX-010; MDX-CTLA-4; Yervoy
Performance Guarantee
If an Invitrogen™ antibody doesn't perform as described on our website or datasheet,we'll replace the product at no cost to you, or provide you with a credit for a future purchase.*
Learn more
We're here to help
Get expert recommendations for common problems or connect directly with an on staff expert for technical assistance related to applications, equipment and general product use.
Contact tech support